Researchers continue to excited about this new drug, a groundbreaking dual agonist showing remarkable outcomes in initial trials for weight loss . It works by impacting both pathways : GLP-1 and GIP, which , when engaged , support control cravings and enhance calorie burn. Initial observations demonstrate noteworthy body loss and possible benefits